Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Inipharm Raises $35 Million in Series A to Focus on Highly Validated ...
Inipharm 2026 Company Profile: Valuation, Funding & Investors | PitchBook
Inipharm to Present Data Showing Potential of Small Molecule Inhibitors ...
Inipharm is a biopharmaceutical company focused on discovering and ...
Home | Inipharm
Jubilant Life Sciences: Jubilant Life arm inks pact to acquire Inipharm ...
Harriet Copping on LinkedIn: Inipharm Initiates Dosing in Phase 1 Study ...
Small biotech Inipharm lands $35M to take new NASH approach, diverging ...
IniPharm Closes on $35 Million Series A to Fund NASH Drug Development ...
BioCentury - Ex-Mavupharma execs reunite at Inipharm to build liver ...
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm study of INI ...
Dan Estes - Director at Inipharm | The Org
Inipharm raises $35M to combat liver diseases with a genetics approach ...
Jubilant Life arm inks pact to acquire Inipharm Inc
Inipharm’s Development Candidate INI-822 Shows Improvements in Markers ...
A轮融资3500万美元，Inipharm通过HSD17B13靶点治疗肝病 欢迎关注 凯莱英 药闻2020年11月11日，Inipharm宣布 ...
Connecting the human intestine and liver - CN Bio
Who we are - CN Bio
5AM Ventures
CN Bio | Organ-on-a-chip company | Human Drug Discovery
Targeting 17β-HSD13: Emerging Patent Landscape in Fibrosis and MASH
CN-Bio器官芯片数据支持肝病候选药物进入临床阶段_上海曼博生物 - 企业动态 - 丁香通
CN Bio：一家经美国FDA验证过的微流控器官芯片系统供应商-公司新闻-上海曼博生物医药科技有限公司
Primary biliary cholangitis: Promising emerging therapies | HMER
Revolutionizing Primary Biliary Cholangitis Care: A Paradigm Change on ...
CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for ...
Improving Treatment for Primary Biliary Cholangitis | myCME
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for ...
CN Bio's PhysioMimix Organ-on-a-Chip Data Validates Inipharm's INI-822 ...
CN Bio PhysioMimix Organ-on-a-Chip Data Validates Inipharm's INI-822 ...
PhysioMimix data supports Inipharm’s INI-822 for metabolic liver ...
Great to be in Washington DC for AASLD - The Liver Meeting 2022 ...
Primary Biliary Cholangitis: The Case Debate
Treating PBC: Unmet Needs and Evolving Treatments | myCME
Health Equity for Patients With Primary Biliary Cholangitis
About Us - uniPHARM
Advancing liver disease treatment with INI-822 - Diabetes Qualified
Known targets and their small molecule inhibitors with respect to ...
UMC Charity - Home
Is Primary Biliary Cholangitis on Your Radar?
Cholestasis unveiled: Navigating Rare Liver Disorders
Innopain
HSD17B13 — Emerging Therapeutic Target in NASH & Liver Disease-DIMA BIOTECH
Digging Deeper into Abnormal Liver Test Results | myCME
Becoming Practice-Ready for Imminent NASH Drug Approvals - Sonic Incytes
Management of Hepatorenal Syndrome–Acute Kidney Injury for the Liver ...
HSD17B13-NASH治疗新兴靶点 - 知乎
In-vitro OOC provides liver disease data | Scientist Live
Jejunum-Hepatocyte Dual-Organ MPS for Drug ADME Studies
CN-Bio器官芯片应用—NASH IND申报_上海曼博生物代理-公司新闻-上海曼博生物医药科技有限公司
Late-Onset Genetic Cholestasis - Cholestasis Unveiled: Navigating Rare ...
BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects ...
The Human Touch: How Liver-on-a-Chip Addresses the Unmet Needs of Liver ...
Technology Networks Science Product News | Technology Networks
Treating Challenging Moderate to Severe Crohn Disease With IL-12/IL-23 ...
Organ-on-a-chip data supports progression of liver disease drug - Drug ...
Unveiling the Secrets of IL-17A Inhibitors: Stay Updated with the ...
PBC Case Closed Slides.pdf
MASH In Vitro Services | Human Fibrosis & Steatosis Assays
Next Level PBC Management: Focus on Recognition, Disease Monitoring ...
HSD17B13-IN-18 | 17β-HSD Inhibitor | MedChemExpress
A closer look at the mysterious HSD17B131 - Journal of Lipid Research
Semaglutide gets FDA approval to treat MASH
Anti-inflammatory nanodrugs for liver injury that exert effects via ...
#drugdiscovery #drugdevelopment #drugsafety #pharmaceuticalindustry # ...
INI-822 treatment alters plasma levels of hydroxy-lipid substrates of ...
Monoclonal Antibody-Based Biological Therapies for IBD | Download Table
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from ...
PhysioMimix® Core Microphysiological System MPS | CN Bio
An unprecedented endocrine target for ovarian cancer: inhibiting 17β ...
